Type 2 diabetes mellitus is a major risk factor for cardiovascular disease. However, compiled data suggest that type 2 diabetes affects the risk of cardiovascular disease differentially according to sex. In recent years, large meta-analyses have confirmed that women with type 2 diabetes have a higher relative risk of incident coronary heart disease, fatal coronary heart disease, and stroke compared with their male counterparts. The reasons for these disparities are not completely elucidated. A greater burden of cardiometabolic risk in women was proposed as a partial explanation. Indeed, several studies suggest that women experience a larger deterioration in major cardiovascular risk factors and put on more weight than do men during their transition from normoglycemia to overt type 2 diabetes. This excess weight is associated with higher levels of biomarkers of endothelial dysfunction, inflammation, and procoagulant state. Moreover, sex differences in the prescription and use of some cardiovascular drugs may compound an "existing" disparity. We searched PubMed for articles published in English and French, by using the following terms: ("cardiovascular diseases") AND ("diabetes mellitus") AND ("sex disparity" OR "sex differences" OR "sex related differences" OR "sex-related differences" OR "sex disparities"). In this article, we review the available literature on the sex aspects of primary and secondary prevention of cardiovascular disease in people with type 2 diabetes, in the predisposition to cardiovascular disease in those people, and in the control of diabetes and associated cardiovascular risk factors. 
D iabetes mellitus is a major risk factor for cardiovascular disease (CVD).
Its prevalence is increasing worldwide, and this trend is projected to persist because of the demographic shift and the obesity pandemic. The global prevalence of diabetes was estimated at 8.8% in 2017, with a slightly higher prevalence among men (9.1%) than among women (8.4%). 1 However, despite large variations in the reported male-to-female ratio between studies in different countries and ethnicities, there is little evidence to support a sex difference in the prevalence of diabetes. Most people with diabetes have type 2 diabetes mellitus (T2DM). On the other hand, CVD is the leading cause of morbidity and mortality in people with diabetes. Modern studies show that CVD is responsible for 24% to 30% of hospitalizations 2 and around one-third of deaths 3, 4 in people with diabetes. Despite improvements in CVD morbidity and mortality during recent decades, the populationattributable risk for diabetes as a cardiovascular risk factor continues to increase 5 and the cardiovascular burden of diabetes remains important.
Although women without diabetes have a lower risk of developing CVD compared with men without diabetes of the same age, this "female advantage" seems to diminish or disappear in the setting of T2DM. Indeed, the relative risk of CVD in people with T2DM compared with people without diabetes is greater in women than in men, whereas the absolute risk of CVD is either comparable between the sexes or the sex difference is much smaller in the presence of T2DM. This greater relative risk was confirmed by large meta-analyses and wellconducted studies ( Figure  1 ; see Supplemental Figure 1 , available online at http://www.mayoclinicproceedings.org). [6] [7] [8] [9] [10] Cardiovascular risk factors (CVRFs) clustering in women and a greater burden of novel (emergent) risk markers, 11 as well as sex differences in the prescription and use of some cardiovascular drugs, were proposed to explain the higher relative risk of CVD in women with T2DM compared with their male counterparts. We therefore undertook this review of the literature concerning sexrelated differences in the prevention of, and predisposition to, CVD in people with T2DM. References for this review were identified through searches of PubMed for articles published in English and French, by using the following terms: ("cardiovascular diseases" [MeSH] OR "cardiovascular . Relevant articles based on the title and abstract were identified and retrieved. Additional articles were then added by searching references cited in the retrieved articles and by searching the authors' personal files. There was no date limitation of our searches, but references published before 2000 were not included unless highly important or not reproduced in more recent research. It is worth mentioning that many studies refer to people with diabetes as a whole and do not distinguish between the different types of diabetes. Therefore, we use the term "diabetes" when the type of diabetes is not clearly noted. Otherwise, the term "T2DM" is used.
SEX-RELATED DIFFERENCES IN THE ASSOCIATION BETWEEN OBESITY AND T2DM AND IN THE IMPACT OF LIFESTYLE INTERVENTION ON CVD Obesity and T2DM
Obesity is the most prominent risk factor for T2DM, and it is present in 37% to 61% of people with T2DM and another 26% to 42% are overweight. 12, 13 A significantly higher proportion of women with T2DM have obesity (estimated by body mass index [BMI] ; calculated as the weight in kilograms divided by the height in meters squared) (P<.001) and central obesity (estimated by waist circumference; see Supplemental Table 1 , available online at http://www. mayoclinicproceedings.org) (P¼.0054) in comparison to their male counterparts. 14 15 Obese people who have T2DM are characterized by higher rates of hypertension and dyslipidemia, which means an increased cardiovascular burden when compared with their nonobese counterparts, regardless of sex. However, even after adjusting for risk factors, obese individuals (with and without diabetes) still have an increased risk for CVD, meaning that obesity mediates CVD by other factors in addition to classical risk factors. 16 Interestingly, studies from Scotland and the United Kingdom showed that men develop T2DM at a lower BMI (z2 kg/ m 2 ) than do women, presumably because of higher insulin resistance. 17, 18 Also, differences in other measures of obesity (waist circumference and waist-to-hip ratio) between individuals with and without T2DM are greater in women than in men. 19 This means that women have to put on more weight (more adipose tissue) to become insulin resistant and develop T2DM. This excess weight is associated with a greater deterioration in the cardiometabolic risk. Supporting these conclusions, the mean differences in CVRF levels between individuals with T2DM and those without were greater for women than for men in a recent meta-analysis ( Figure 2 ). 6 Lifestyle Interventions for the Prevention of CVD in People With T2DM Lifestyle interventions to improve dietary quality, increase physical activity, and obtain weight loss are indicated for people with T2DM because of their favorable effects on metabolic abnormalities and CVRFs. However, few studies have reported results of lifestyle interventions in people with T2DM in terms of the long-term occurrence and mortality of CVD. The Japan Diabetes Complications Study showed a significant reduction in the incidence of stroke among 2033 Japanese people with T2DM randomized to lifestyle intervention (P¼.04), but the incidence of coronary heart disease (CHD) was not different between the intervention group and the control group. The intervention effect was not different between the sexes. 20 The Action for Health in Diabetes (Look AHEAD) study randomized 5145 individuals with T2DM from 16 centers in the United States (of whom 14% had CVD at baseline) to lifestyle intervention or usual care, and demonstrated no benefit on CVD 21 ; the intervention effect was comparable between the sexes. Findings from a post hoc analysis of the Look AHEAD study suggest that individuals who lost 10% or more of their body weight in the first year of the study had a significant reduction (P¼.034) in the occurrence of primary CVD outcomes (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for angina), with no interaction between weight loss and sex. 22 The PREDIMED (Prevención con Dieta Mediterránea) study examined the effect of a Mediterranean diet supplemented with extra-virgin olive oil or with mixed nuts vs a control diet in the primary prevention of CVD. Among the 7447 randomized individuals, 4282 (57.5%) were female and 3614 (48.5%) had T2DM at baseline. The supplemented Mediterranean diet resulted in a relative risk reduction of approximately 30% in the occurrence of major adverse cardiovascular events (MACE) in the whole study population as well as in the diabetic subgroup. The effects of a supplemented Mediterranean diet were similar between the sexes regardless of diabetes status. 23 The impact of lifestyle intervention on CVD, especially on cardiovascular mortality, takes a long time to emerge. The Da Qing study randomized 577 Chinese individuals with impaired glucose tolerance into 1 of 4 groups: diet-only intervention, exerciseonly intervention, diet plus exercise intervention, and usual care. The difference between the intervention group (composed of the 3 intervention subgroups) and the control group in terms of cardiovascular mortality became significant only after 23 years of follow-up (P¼.033). 24 Interestingly, in this study, the reduction in cardiovascular mortality occurred mainly in women (hazard ratio [HR]¼0.28; 95% CI, 0.11-0.71; P¼.01), but there was an imbalance between the sexes at baseline (men were older and more likely to be smokers).
ARTICLE HIGHLIGHTS

SEX-RELATED DIFFERENCES IN THE PREVALENCE AND CONTROL OF CLASSIC CARDIOVASCULAR RISK FACTORS IN PEOPLE WITH T2DM
Good control of classic CVRFs is of paramount importance in the primary and secondary prevention of CVD. We will consider each risk factor separately.
Hypertension
Hypertension is the most important risk factor. Its prevalence in people with T2DM is double that in the general population (59.4% vs 29.6% in the United States). 25 Although hypertension is more common in men with diabetes before the age of 60 years, it becomes more common in women with diabetes after the age of 60 to 65 years. 15 This is related, at least partially, to declines in estrogens' levels and signaling after menopause. Elevated blood pressure (BP) in the presence of T2DM is associated with an incremental increase in the cardiovascular risk, in a continuous fashion, in both sexes. Each 10-mm Hg lower BP step in people with T2DM is associated with a considerable reduction in CVD until a target systolic BP toward 130 mm Hg. Targeting systolic BP of less than 130 mm Hg is associated with fewer strokes but no further reduction in other major CVDs is observed. 26 So, the BP targets to be achieved are still debated (<140/90 or <130/80 mm Hg). The cardiovascular benefit seems to be dependent more on the achieved BP levels than on the drug used to achieve this target. Regardless of BP targets, many cross-sectional studies that looked at the sex aspect in the control of hypertension in people with T2DM found that hypertension is less well controlled in women than in their male counterparts (Table 1) . 30, 31, 33, 34, [37] [38] [39] [40] [41] [42] Few studies have examined the difference in antihypertensive classes between sexes. Women with T2DM are more likely to be prescribed diuretics and beta blockers 43 and less likely to receive angiotensin-converting enzyme inhibitors [44] [45] [46] and calcium channel blockers than are men with T2DM. 43, 47 Dyslipidemia Type 2 diabetes mellitus is associated with a cluster of lipid abnormalities (diabetic dyslipidemia) that include elevated triglyceride levels, decreased high-density lipoprotein (HDL) cholesterol levels, and an increase in small, dense low-density lipoprotein (LDL) particles. Dyslipidemia is present in most people with T2DM. 48 It appears to be more frequent in women with T2DM after the age of 60 years than in men with T2DM of the same age group. 15 Again, this may be due to declines in estrogens' levels and signaling after menopause. In a large sample of people with T2DM from Sweden, women had significantly higher levels of total, LDL, and HDL cholesterol (P<.001 for all) when compared with men. Triglyceride levels were lower in women in the youngest age group (40-54 years) but higher in elderly women (!70 years) when compared with age-matched men. 49 Nowadays, statins represent the mainstay of dyslipidemia treatment and are indicated for primary prevention in most people with diabetes as well as for secondary prevention.
d In primary prevention, the Cholesterol Treatment Trialists' Collaboration analyzed individual participant data from 14 trials of statin therapy and found a considerable 27% relative risk reduction per 1 mmol/L reduction in LDL cholesterol in major vascular events in people with diabetes without known CVD. However, most of the evidence concerns men, because they represented more than 67% of participants in this analysis. 50 Indeed, women are underrepresented in primary prevention trials of statin therapy (in both diabetic and nondiabetic populations), a fact that hampers evidencebased conclusions concerning the effect of statin therapy for primary prevention in women. In a recent meta-analysis, women (with and without diabetes) allocated to statin therapy for primary prevention had a lower relative risk reduction for major vascular events when compared with men (15% vs 28% per 1 mmol/L reduction in LDL cholesterol; P¼.023 for heterogeneity), but the authors did not present stratified results for the diabetic subgroup. 51 However, the difference may be related to the lower cardiovascular risk in women. In the same meta-analysis, allocation to statin therapy (primary and secondary prevention) was associated with an absolute reduction of 1.1 mmol/L at 1 year in men and 1 mmol/L in women (P¼.01 for heterogeneity). No stratified results were presented for the diabetic subgroup. So, statin therapy for primary prevention seems to be as effective in women as it is in men provided that they are at equivalent risk of CVD. d In secondary prevention, the efficacy of statin therapy is similar in the 2 sexes in randomized trials. 50 Nevertheless, some studies found that women with T2DM were less likely to be prescribed statin (or lipidlowering treatment) when compared with male counterparts. 41, 45, [52] [53] [54] Moreover, numerous observational and cross-sectional studies had shown that a lower proportion of women with T2DM were on target regarding LDL cholesterol when compared with men (Table 2) .
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d Importantly, when mean LDL cholesterol levels (or the on-target percentage) were stratified according to statin therapy, women on statin therapy 54 and untreated women tended to have worse control of LDL cholesterol than men. 32, 27 The reasons for such a disparity are not completely understood, but it is possible that female sex per se confers higher LDL cholesterol levels. Nonadherence to statin therapy in women with T2DM (because of adverse effects or cost) may be partially responsible for this difference in the treated group, as suggested by some authors. 28 Of note, female sex is associated with a higher risk of statin-associated muscle symptoms 59 although these symptoms are especially reported in observational studies but not in randomized controlled ones. 60 Other drugs are also used as second-line treatment to treat diabetic dyslipidemia. Ezetimibe as an add-on to statin therapy improved MACE in people with diabetes, and its effect seems to be comparable between women and men. 61 Fenofibrate reduced the occurrence of total CVD in people with T2DM when used in individuals without statin, 62 whereas it failed to do so when added to statin therapy. 63 Interestingly, the results of the ACCORD study demonstrated that fenofibrate as an add-on to statin therapy was associated with a possible benefit for men and possible harm for women (P¼.01 for interaction by sex). A subsequent analysis of the data from the FIELD study concluded that fenofibrate reduced CVD similarly in both sexes. 64 Recently, evolocumab led to a substantial reduction in cardiovascular outcomes in people with diabetes who were on statin therapy. 65 The authors did not report separate HR values for men and women with diabetes but, in the original study (people with and without diabetes), evolocumab reduced cardiovascular outcomes similarly in both sexes. 66 
Smoking
Tobacco smoking is an independent risk factor for CVD that is associated with considerably increased relative risk of cardiovascular death and CVD in people with diabetes when compared with people with diabetes who do not smoke. Recent meta-analyses suggest that the combination of smoking and diabetes confers a higher relative risk of CHD and a lower relative risk of stroke in women compared with men, 67, 68 although more studies are needed to confirm such associations.
The prevalence of smoking in people with diabetes varies widely across studies, but it remains relatively high. Worldwide, a far higher proportion of men than women in the general population smoke tobacco, whereas among people with diabetes this sex gap is attenuated. However, the global estimation of the populationattributable fraction for cardiovascular death and CVD remains about 4 times higher in men with diabetes than in women with diabetes. 68 Smoking cessation is accompanied by a reduction in the risk of CVD in comparison to ongoing smoking, and its effects are broadly the same in both sexes. 69 Of note, smoking cessation is followed by weight gain, but this does not seem to offset the cardiovascular benefit. 70 This subject needs further research to determine whether women gain more or less weight than do men after smoking cessation.
SEX-RELATED DIFFERENCES IN THE MANAGEMENT OF T2DM Diabetes Control
In the past, studies of CVD in people with T2DM focused more on treatment targets than on drug choices. However, despite abundant evidence on the association between hyperglycemia and increased cardiovascular risk, intensive glucose control did not reduce cardiovascular mortality in randomized controlled trials. A small reduction in the risk of nonfatal myocardial infarction and lower limb amputation was found in some meta-analyses. 71, 72 None of these studies provided evidence to suggest that the effect of intensive glucose control on CVD differs by sex, except for a recent meta-analysis that suggested a significant reduction in MACE (P¼.022) only in studies with a male percentage of less than 70% when compared with studies composed of 70% or more men. 73 However, the interaction test was not significant (P¼.724). Therefore, to reduce the risk of CVD in people with T2DM, guidelines targeted comprehensive control of CVRFs, as proposed by the Steno 2 study. 74 In this setting, many cross-sectional studies have found that women with T2DM have worse control of diabetes (higher glycated hemoglobin A 1C levels or lower proportion ontarget compared with men) with 75 or without poor control of other CVRFs (Table 3) . [32] [33] [34] [35] 37, 41, 42 Pharmacotherapy for T2DM Little is known about sex disparities in the effects of older antidiabetic drugs on CVD. It appears that the effects of metformin, 76 rosiglitazone, 77 pioglitazone, 78 nateglinide, 79 and acarbose 80 on CVD are not different between the sexes. A recent study from Italy compared the effects of pioglitazone vs sulfonylurea as add-on treatments with metformin on CVD in people with T2DM. The incidence of the primary outcome (all-cause death, nonfatal myocardial infarction including silent myocardial infarction, nonfatal stroke, or urgent coronary revascularization) was similar for both drugs and the effect was comparable in both sexes. 81 In 2008, the US Food and Drug Administration issued guidance for industry that required the demonstration of cardiovascular safety of new antidiabetic drugs and recommended exploring the occurrence of CVD in subgroups determined by sex. Members of the dipeptidyl peptidase 4 inhibitors were the first drugs to be evaluated after this guidance. Their effects on CVD were found to be noninferior (and nonsuperior) to placebo in randomized controlled trials, and there was no sex heterogeneity in the occurrence of MACE. [82] [83] [84] Of note, the rate of hospitalization for heart failure was increased with saxagliptin. 85 Recently, 2 classes of new antidiabetic drugs, which have favorable effects on CVRFs beyond their effects on hyperglycemia, showed a beneficial effect on CVD in people with T2DM, further supporting the need to simultaneously control many CVRFs:
-Two human glucagon-like peptide 1 receptor agonists showed favorable effects on CVD in people with T2DM. Liraglutide significantly reduced the occurrence of MACE in people with T2DM (P<.001); 87 Whether these results reflect a true sex difference or are the result of inadequate statistical power (related to underrepresentation of women) remains to be established although the latter possibility seems more probable. In contrast, lixisenatide and weekly exenatide did not decrease or increase the occurrence of MACE in people with T2DM when compared with placebo, regardless of sex. 88, 89 -Inhibitors of sodium-glucose cotransporter 2 proved effective in reducing the occurrence of MACE in people with T2DM. Although the HR for MACE was comparable between sexes in the EMPA-REG OUTCOME (cardiovascular outcome trial of empagliflozin) trial, the decrease in cardiovascular mortality was significant only in men (but not in women) treated with empagliflozin. 90 Again, the number of men (4687 participants) was twice the number of women (2333 participants), which raises questions of statistical power. Canagliflozin showed a similar reduction in MACE in both sexes. 91 Moreover, results from an observational analysis from Denmark, Norway, and Sweden (22,830 users of sodium-glucose cotransporter 2 inhibitors) suggest an equivalent effect on MACE between men and women. 92 Concerning insulin therapy, insulin glargine neither reduced nor increased cardiovascular outcomes in individuals with hyperglycemia, with similar results between sexes. 93 Recently, insulin degludec was compared with insulin glargine for its cardiovascular safety. Degludec was not inferior to glargine with respect to the incidence of MACE, although the results of subgroup analyses favored degludec in women (HR, 0.76; 95% CI, 0.76-0.99 for women vs HR, 0.99; 95% CI, 0.83-1.20 for men; P¼.099 for interaction by sex). 94 
SEX-RELATED DIFFERENCES IN ANTIPLATELET THERAPY FOR PREVENTION OF CVD IN PEOPLE WITH T2DM Primary Prevention
The platelets of people with diabetes are characterized by several abnormalities in their functions (enhanced adhesion, activation, and aggregation), leading to increased reactivity. They also have an accelerated turnover, leading to a larger number of less mature platelets entering the circulation. Augmented oxidative stress and impaired endothelial function further participate in platelet dysfunction in diabetes, which plays a pivotal role in atherothrombosis. Nevertheless, the effectiveness of aspirin therapy for primary prevention of CVD in people with diabetes remains unproven. Randomized controlled trials report conflicting results, whereas 7 meta-analyses that included different combinations of trials concluded that aspirin is not associated with a statistically important reduction in CVD. 95 Interestingly, 3 of these meta-analysis suggested differences in the effect of aspirin according to sex: De Berardis et al 96 reported that aspirin significantly reduced the risk of myocardial infarction in men (P¼.03) but not in women 96 ; Zhang et al 97 reported a lower relative risk for myocardial infarction in trials with a male percentage of 50% or more and a lower relative risk for stroke in trials with a male percentage of less than 50%; and Kunutsor et al 98 found that aspirin significantly reduced MACE in men (P¼.033) but not in women. Data from the Swedish National Diabetes Register showed an increased risk of CHD in women with T2DM who received aspirin for primary prevention. 99 However, these results concerning sex-related differences in the effects of aspirin should be interpreted with caution because of limited subgroup analyses and a subsequent lack of statistical power.
Furthermore, these differences were not consistently found in studies of aspirin for primary prevention in the general population, 100 nor were they continuously observed in secondary prevention trials in people with diabetes. 101 Hopefully, the results of ongoing studies, including A Study of Cardiovascular Events iN Diabetes (ASCEND) and Aspirin and Simvastatin Combination for Cardiovascular Event Prevention Trial in Diabetes (ACCEPT-D), will shed further light on the impact of sex on aspirin effects. The first trial, ASCEND, has recruited 15,480 individuals with diabetes 102 and ASCEND's results are expected in 2018, whereas ACCEPT-D has recruited 5170 individuals with diabetes but no fixed date is provided for the results because ACCEPT-D is an event-driven study. 103 
Secondary Prevention
The efficacy of aspirin for secondary prevention of CVD is undisputed in both sexes. Nevertheless, many studies have suggested that aspirin is underused in women with T2DM, 104, 105 notably for secondary prevention. 31, 33, 41, 53, 106 Dual antiplatelet therapy is often needed for patients with acute coronary syndromes, especially those undergoing percutaneous coronary intervention. There are only sparse data about sex-related differences in the action of other antiplatelet drugs in people with T2DM. Indirect evidence suggests that clopidogrel and ticagrelor are as effective in women with diabetes as in male counterparts. 107 Prasugrel was associated with a trend toward a larger reduction in MACE in men with diabetes than in female counterparts. 108 
SEX-RELATED DIFFERENCES IN THE PREVALENCE AND EFFECTS OF NOVEL (EMERGENT) RISK MARKERS OF CARDIOVASCULAR RISK
Excess risk of CVD in people with T2DM is not fully explained by traditional CVRFs. Moreover, the greater relative risk of CVD in women with T2DM is not completely accounted for by those CVRFs. Chronic low-grade inflammation, endothelial dysfunction, and procoagulant state play an important role in the pathogenesis of atherothrombosis in people with T2DM. Therefore, investigators looked for the association between biomarkers of inflammation, endothelial dysfunction, and hypercoagulability on one hand and the development of CVD in people with T2DM on the other hand. Only scanty evidence exists concerning sex-related differences in these biomarkers; results are not always consistent and sometimes conflicting results were reported. It is important to note that these biomarkers are interconnected but they are represented separately for the sake of simplification.
Endothelial Dysfunction
It is widely accepted that T2DM and the accompanying hyperglycemia/insulin resistance alter the endothelial function and contribute to the development of CVD in people with T2DM. When damaged, endothelial cells secrete molecules such as von Willebrand factor and express adhesion molecules such as vascular cell adhesion molecule 1, intercellular adhesion molecule 1, and E-selectin. It is worth mentioning that estrogens reduce the expression of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 by endothelial cells via nongenomic mechanisms and participate in maintaining the endothelial function. 109 von Willebrand factor has been linked to the development of CVD and cardiovascular mortality in people with T2DM, whereas E-selectin was found to be associated with CVD in those people but none of these results were stratified by sex.
Women without diabetes have a more healthy endothelial function, as assessed by endothelium-dependent vasodilation, when compared with men. In contrast, women and men with T2DM have similar endothelial dysfunction, suggesting that women deteriorate their endothelial function to a greater extent before being diagnosed with T2DM. 110 One study found that the differences in von Willebrand factor levels between individuals with and without T2DM were more pronounced in women than in men (P¼.04 for interaction by sex). 111 However, these results still need to be confirmed.
INFLAMMATION
Different markers of inflammation were evaluated to assess their relation to the development of CVD in people with T2DM. The list includes, among others, white blood cells, C-reactive protein (CRP), interleukin-6 (IL-6), fibrinogen, tumor necrosis factor-a, and interleukin-1 receptor antagonist. Detailed description of the role of these markers in the pathophysiology of CVD in people with T2DM is beyond the scope of this review, and we report only those results that are related to the sex aspect (difference between sexes in the prevalence or effect of these markers):
d Point estimate for the association between inflammatory markers (especially CRP and fibrinogen) and cardiovascular end points were generally comparable between men and women with T2DM.
112
Only 1 study found an association between CRP and coronary artery calcification (subclinical atherosclerosis) in women with T2DM but not in men (P<.001 for interaction).
113
d A study from Finland found that women with T2DM had higher levels of inflammatory markers (high-sensitivity CRP and interleukin-1 receptor antagonist) when compared with men with T2DM. Interestingly, women experienced a greater increase in inflammatory markers during their travel from normal glycemia to T2DM than did men. 114 Similar patterns were found in the Strong Heart Study (fibrinogen) 115 and in an analysis of data from the British Regional Heart Study and British Women's Heart Health Study. 111 However, the latter analysis did not find any difference between sexes in CRP or IL-6 levels, whereas others had found that women with T2DM had higher levels of CRP (with or without IL-6 or fibrinogen) when compared with male counterparts. [116] [117] [118] [119] Put together, these results point toward a higher burden of inflammation in women with T2DM compared with male counterparts.
Coagulation
Type 2 diaetes mellitus is characterized by an imbalance between anticoagulant factors and procoagulant ones that favors procoagulant factors and, coupled with decreased fibrinolysis, contributes to the increased risk of atherothrombosis. Some studies had found that women with T2DM, when compared with male counterparts, had higher levels of factor VII coagulant activity, 120,121 factor VIII, 111 and/or plasminogen activator inhibitor-1, 121,122 a potent inhibitor of fibrinolysis that was found to be associated with CVD (especially peripheral arterial disease) among people with T2DM. Regardless of coagulation factors and plasminogen activator inhibitor-1 levels, Alzahrani et al 122 analyzed clot structure/fibrinolysis in 875 individuals with T2DM and found that women, when compared with men, had compact fibrin clot resistant to fibrinolysis "prothrombotic phenotype." Increased BMI and decreased HDL cholesterol were associated with the "prothrombotic phenotype" in women, whereas hyperglycemia was associated with adverse clot phenotype in men. 122 Together, these quantitive and qualitative changes in coagulation/fibrinolysis could be partly responsible for the increased relative risk of CVD in women with T2DM (Table 4) .
WOMEN WITH HIGH RISK TO DEVELOP T2DM AND CVD
Unfortunately, once women are diagnosed with T2DM, they have already acquired a higher relative risk to develop CVD and it may be too late to reverse this high-risk status. Therefore, it is necessary to implement preventive measures for high-risk groups and to provide optimal management for women with prediabetes. Overweight and obese women, especially those with central obesity, are particularly at risk of developing T2DM. Postmenopausal women are also at risk to develop T2DM and CVD. In fact, menopausal transition is associated with increased adiposity and changes in fat distribution, which contributes to insulin resistance and T2DM although the impact of estrogens' loss per se on the incidence of T2DM remains unclear. 109, 123 Other highrisk groups include women with gestational diabetes and those with polycystic ovary syndrome. Interestingly, these 2 latter conditions represent 2 natural models of hyperglycemia and insulin resistance (the mechanisms at interplay in T2DM) that could help to understand the pathogenesis of the increased cardiovascular risk in women with T2DM. Women with gestational diabetes have a 7-fold increased risk of developing T2DM, 124 and limited data suggest an increased risk of subsequent CVD. Women with polycystic ovary syndrome usually have insulin resistance, an androgen excess, and a higher prevalence of obesity and impaired glucose tolerance (or T2DM), but no large prospective cohort studies have been undertaken to confirm or negate the increased risk of subsequent CVD. Finally, women with hypertensive pregnancy disorders are at increased risk to develop T2DM and CVD. 125 
CONCLUSION
The main conclusions of our review are the following:
-Women with T2DM have been underrepresented in clinical trials focusing on CVD in general and in trials of statins in particular. Moreover, sex-specific analyses were often absent. -The LDL cholesterol is less well controlled in women with T2DM, partly because of insufficient use of statins. -During their transition from normoglycemia to T2DM, women put on more weight and accumulate a higher cardiometabolic risk burden, with a greater deterioration of endothelial function, inflammation, and hypercoagulability states than do their male counterparts. -Aspirin might be underused in women with T2DM for secondary prevention of CVD, and is not beneficial for primary prevention. -Blood pressure and diabetes seem to be less well controlled in women with T2DM compared with male counterparts. -Some of these sex disparities, such as higher BMI at diagnosis of T2DM in women, are biological in nature, that is, related to female sex. The other dimension of these disparities (underuse of evidencebased treatment in women and underrepresentation of women in clinical trials) is of a psycho-socio-cultural nature and often coexists with other disparities related to socioeconomic status, race, 54 or ethnicity. Low socioeconomic status is associated with unhealthy behaviors and with a higher prevalence of obesity and T2DM. Moreover, social, psychological, and cultural factors could influence health care access, adherence to health care interventions, engagement in healthy lifestyles, and participation in clinical trials. Thus, health care authorities should empower women, offer them equitable access to health care, and promote strategies that encourage women to adhere to health care interventions and to adopt healthy lifestyles. Moreover, health care authorities should promote high-quality research on sex differences in general and among people with diabetes in particular. Finally, health care authorities and medical societies must do more to ensure that the female half of the population is no longer represented by less than one-third of participants in clinical trials.
Abbreviations and Acronyms: ACCEPT-D = Aspirin and Simvastatin Combination for Cardiovascular Event Prevention Trial in Diabetes; ASCEND = A Study of Cardiovascular Events iN Diabetes; BMI = body mass index; BP = blood pressure; CHD = coronary heart disease; CRP = C-reactive protein; CVD = cardiovascular disease; CVRF = cardiovascular risk factor; HDL = high-density lipoprotein; HR = hazard ratio; IL-6 = interleukin 6; LDL = low-density lipoprotein; MACE = major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke); T2DM = type 2 diabetes mellitus
